Ep. 313 - Lessons from FDA's Prasad. Plus: What's next for Novo, Bayer

The ouster of Vinay Prasad after three months running FDA’s Center for Biologics Evaluation and Research could signal a reset is ahead for CBER. On the latest BioCentury This Week podcast, BioCentury’s analysts discuss what the latest shakeup at the regulatory agency says about what’s next for FDA. The analysts also assess two leading European pharmas: obesity and diabetes company Novo Nordisk, which named a new CEO last week while cutting its 2025 forecast, and Bayer, which is gearing up for launches and is revamping its pipeline to restart growth. Finally, they discuss the promising clinical data that’s reviving interest in masking technologies that conditionally activate biologics. View full story: https://www.biocentury.com/article/656649 #FDA #CBER #NovoNordisk #ObesityDrugs #Bayer 01:05 - Prasad"s Ouster 14:59 - Novo"s New CEO 21:14 - Bayer"s Growth Strategy 26:05 - Masked Biologics To submit a question to BioCentury’s editors, email the BioCentury This Week team at podcasts@biocentury.com. Reach us by sending a text